Beth Moore, MD
Colon & Rectal Surgery · West Hollywood, CANPI 1720139488
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,082 of the $4,047 with a category attached, or 76.2%. 24 manufacturers reported payments, led by Intuitive Surgical at 41.7% of the total. Reporting peaked in 2022 at $1,531 and has fallen 85.7% since, to $220 in 2024. That places this record below the midpoint for colon & rectal surgery clinicians in CA, where the typical reported total is $3,373.
Across 119 payments — averaging $34.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$2K
- Ferring Pharmaceuticals Inc.$748
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$386
- THD America, Inc.$170
- Takeda Pharmaceuticals U.S.A., Inc.$143
- Prescient Surgical$139
- plus $772 from 18 others
Across 1 payment — averaging $23,490 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$23K
What the payments were for
- Travel & lodging$90522%
- Food & beverage$3,08276%
- Education$70%
- Gifts$541%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 13 | $1,688 |
| Ferring Pharmaceuticals Inc. | 40 | $748 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 27 | $386 |
| THD America, Inc. | 1 | $170 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $143 |
| Prescient Surgical | 1 | $139 |
| Medtronic | 1 | $113 |
| Braintree Laboratories, Inc. | 3 | $86 |
| Exact Sciences | 3 | $74 |
| AstraZeneca | 3 | $72 |
| Endo Pharmaceuticals Inc. | 3 | $63 |
| Novo Nordisk | 3 | $55 |
| Merck | 3 | $47 |
| Palette Life Sciences, Inc. | 2 | $47 |
| Acell, Inc. | 2 | $39 |
| Vioptix Inc | 1 | $29 |
| Teleflex LLC | 1 | $26 |
| Covidien LP | 1 | $23 |
| Puma Biotechnology, Inc. | 1 | $21 |
| Zyla Life Sciences, Inc. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Shionogi Inc | 1 | $13 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$1,351
- CleanCision$139
- INTERSTIM$113
How this compares
$4,047 in reported general payments places this provider in the 50th percentile of 176 colon & rectal surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 71 | $11,928 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 137 | $8,746 |
| Mesalamine DrMesalamine | 11 | $3,940 |
| Hydrocortisone | 152 | $2,108 |
| Procto-Med HcHydrocortisone | 73 | $814 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 13 | $645 |
| Proctozone-HcHydrocortisone | 12 | $130 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Ferring Pharmaceuticals Inc.Clenpiq | $748 | $11,92871 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 176 colon & rectal surgery providers in California.
Other colon & rectal surgery in West Hollywood
- Phillip FleshnerWest Hollywood$95K
- Sang LeeLos Angeles$2.4M
- Pamela LeeSan Diego$544K
- Elizabeth RaskinSacramento$126K
- Shohrat AnnaberdyevRoseville$101K
- Alessio PigazziLos Angeles$100K
- Joseph CarmichaelOrange$99K
- Zuri MurrellBeverly Hills$86K
- Lorenc MalellariBakersfield$78K
- Ankit SarinSacramento$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.